1	Moving targets for hyperlipidemia and hypertension
2	Burden of CVD and relation to RF
3	Potential Benefit of Blood Pressure and Cholesterol Lowering on Death (per 10,000 Patient-Years)
4	Dyslipidemia Accounts for More Than Half of Acute MI Risk
5	Lipid-Lowering Therapy Accounted for Over 70% of Cardiovascular Risk Reduction in Patients With Diabetes*
6	Cardiovascular Mortality Increases Sharply With Serum Cholesterol Concentration in Patients With Diabetes
7	הורדת כולסטרול מפחיתה סיכון !
8
9
10
11
12	LDL cholesterol goals according to risk factors group
13
14	Most patient with CAD have “normal” LDL
15	PROVE-IT: Primary End Point By 4-Month LDL Level (Multivariable Adjustment)*
16	PROVE IT: Clinical Outcome by 30-Day Achieved LDL and CRP Levels
17
18
19	Prevalence of IVUS-Detected Coronary Artery Atherosclerosis
20
21	Relationship between LDL-C levels and change in percent atheroma volume for several IVUS trials
22	ASTEROID Trial: Principal Findings
23
24	מתי יש תועלת ממתן סטטינים לאנשים עם LDL נמוך ?
25	Predictive Value of CRP and Other Inflammatory Markers: LDL <130 mg/dL
26
27	נתוני הבסיס של החולים שנכללו בשתי הקבוצות ביופיטר
28	ערכי המעבדה בשתי הקבוצות ללא טיפול
29	נתוני בסיס בהשוואה למחקרים קודמים של מניעה ראשונית
30	התוצאות לאורך זמן
31	תוצאות המחקר בזמן הפסקתו
32	הNNT המשוערך לזמן המקסימאלי
33	מרכיבי התוצאות
34	פירוט כמותי של התוצאות.
35	תת קבוצות
36	תת קבוצות
37	התוצאה טובה מהמצופה!
38	התוצאה טובה מהמצופה !
39	גם תמותה כוללת פחתה!
40	תופעות לוואי
41	סטטינים וסוכרת חדשה
42	מי מועמד לטיפול בסטטינים למניעה ראשונית?
43	Lipid Treatment Guidelines: Which Diabetes Patients Should Be Treated?
44
45	Relationship between LDL-C levels and change in percent atheroma volume for several IVUS trials
46
47	השינוי בלחצי הדם עקב טורסטרפיב
48	Risk of cardiovascular disease events by hypertensive status in the Framingham Study
49	Impact of pulse pressure at specified levels of systolic blood pressure (Framingham)
50	Elevated SBP Increases CVD Mortality
51
52	Cardiovascular Mortality Risk with 20/10 mmHg Increments in SBP/DBP*
53	Lowering blood pressure reduces cardiovascular risk
54
55	Results of randomised trials of antihypertensive drug therapy
56	ככל שהסיכון גבוה הטיפול בלחץ דם יעיל יותר
57
58	Reducing target-organ damage
59	Effects of Antihypertensive Drug Treatment on BP in Trials on Essential Hypertensive Patients
60	Effects of Antihypertensive Drug Treatment on BP in Trials on Essential Hypertensive Patients with Diabetes
61	Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease
62	Strong heart study
63	Strong heart study
64	Number Needed to Treat (NNT) in UKPDS for BP and Blood Sugar Control: BP is More Important
65
66
67	Pharmacological Treatment of Prehypertension
68	Pharmacological Treatment of Prehypertension TROPHY Trial: Incidence of New-Onset Hypertension
69	NORMALISE Results—IVUS LOWESS Plots
70
71
72
73	Normal and Optimal Values of a Physiological Parameter In the majority of physiological parameters optimal and normal values are equal: e.g. – body temperature, serum Na etc There are however parameters where normal values are significantly different from optimal: BP, Lipids, Weight, Insulin resistance, Coagulation etc As health care providers (society) we can either wait for nature to take it’s course or intervene early to optimize “normal” values
74	הגדרות ESH
75	מתי להתחיל טיפול תרופתי בלחץ דם? (לפי (ESH
76	Target Values for Blood Pressure
77	Guidelines Recognise Growing Treatment Complexities and Recommend Tighter Control
78	AHA Scientific Statement: Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease
79	ABPM by treatment for HTN ואולי לא מזהים את כל מי שבסיכון?
80	Hypertension management: Blood pressure control
81
82	Goals are Often Not Met The majority of hypertension is not controlled “A major obstacle is the reluctance of physicians to treat high BP early, intensively, and persistently” “They” are blaming us!
83	Antihypertensive Drugs: Fixed-dose Combinations Potential advantages: Enhanced efficacy Attenuated class-specific side effects Improved compliance Cost-effectiveness
84
85
86	Benefit of Multifactorial Interventions
87	Multiple CV Risk Management Results in Dramatic Reductions in CVD
88	BP control and events
89	Non-adherence to cardioprotective medications is associated with adverse outcomes
90	Improved Outcomes Achieved in Clinical Trials with Higher Adherence